MS tagged posts

Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

Over-the-Counter antioxidant lipoic acid holds promise in improving patients’ lives after an OHSU pilot study. Treatment options currently are limited for people suffering from secondary progressive MS. The randomized double-blind study involved 51 participants who completed the 2-year trial. 27 people were given a 1,200-milogram daily dose of lipoic acid, with the remaining 24 participants given a placebo. Researchers are using the findings from the pilot trial to design the expanded multi-site clinical trial to begin later this year in Portland and other sites that have yet to be finalized.

“These are high doses,” said Rebecca Spain, M.D...

This image shows restored presence of proteins indicating myelin reformation (shown in red) in the lumbar spinal cord of a mouse treated with miR-219 mimic after injury to its central nervous system. Researchers report March 27 in Developmental Cell treatment with the micro-RNA partially repaired damaged nerves and restored limb function in mice. Credit: Cincinnati Children’s

Scientists partially re-insulated ravaged nerves in mouse models of multiple sclerosis (MS) and restored limb mobility by treating the animals with a small non-coding RNA called a microRNA...

Gut microbiota of MS patients differs from healthy controls.

MS patients show lower levels of good bacteria. “Every human carries trillions of bacteria in their gut (gut microbiome) and recent advances in research indicate that these tiny passengers play an important role in our overall health maintenance,” says Ashutosh Mangalam, PhD, assistant professor of pathology at the University of Iowa Carver College of Medicine.

Since the bacteria are associated with contributing to good health, Mangalam and his colleagues wondered whether those with a chronic autoimmune disorder, such as multiple sclerosis, would then have a gut microbiome that is different than the microbiome found in healthy individuals...

Phase III clinical trials has been released for its multiple scleroses drug ocrelizumab, for use in relapsing forms of the disease or in cases of primary progressive multiple sclerosis (PPMS)—and the results appear to be very promising.

Ocrelizumab is a recombinant humanized monoclonal antibody against immune B cells that express CD20 proteins at their surface. These cells are thought to be a key contributor to the myelin and neuron damage that leads to motor function impairment, irreversible neurological disability and paralysis in MS patients. “B cells can contribute to the pathophysiology of MS,” explained Dr. Hauser during his presentation, “targeting CD20-B cells may preserve B cell reconstitution and long-term immune memory.”

85% of patients with MS experience relapse, wit...